Adlai Nortye (NASDAQ:ANL) Shares Climb 10.9% – Time to Buy?

Posted by Brenda Bartman on Oct 17th, 2026

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL – Get Free Report) shares rose 10.9% on Thursday. The company traded as high as $12.46 and last traded at $12.0650. Approximately 182,348 shares changed hands during mid-day trading, a decline of 50% from the average daily volume of 366,404 shares. The stock had previously closed at $10.88.

Analyst Ratings Changes

A number of brokerages have recently issued reports on ANL. Wall Street Zen raised shares of Adlai Nortye from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Loop Capital set a $49.00 target price on shares of Adlai Nortye in a research note on Tuesday, September 8th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Adlai Nortye in a report on Tuesday, September 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Adlai Nortye in a research note on Monday. Finally, Cantor Fitzgerald started coverage on Adlai Nortye in a research note on Monday, June 22nd. They issued an “overweight” rating for the company. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.50.

View Our Latest Stock Report on Adlai Nortye

Adlai Nortye Trading Down 8.8%

The business’s fifty day simple moving average is $14.44 and its 200-day simple moving average is $12.71.

Insiders Place Their Bets

In other Adlai Nortye news, Director Ping Ji sold 10,000 shares of the stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $15.99, for a total transaction of $159,900.00. Following the completion of the transaction, the director owned 121,453 shares of the company’s stock, valued at $1,942,033.47. This represents a 7.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Xiaofeng Ye sold 5,667 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $14.25, for a total value of $80,754.75. Following the transaction, the chief financial officer owned 147,757 shares of the company’s stock, valued at approximately $2,105,537.25. The trade was a 3.69% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 26,881 shares of company stock worth $411,060.

Hedge Funds Weigh In On Adlai Nortye

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SmartHarvest Portfolios LLC grew its holdings in shares of Adlai Nortye by 8.5% in the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after purchasing an additional 1,279 shares in the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Adlai Nortye during the 1st quarter valued at about $457,000. Seven Fleet Capital Management LP purchased a new stake in shares of Adlai Nortye during the 2nd quarter valued at about $1,302,000. ADAR1 Capital Management LLC bought a new position in shares of Adlai Nortye in the 1st quarter valued at about $816,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Adlai Nortye in the 1st quarter valued at about $1,140,000. 35.21% of the stock is owned by institutional investors.

Adlai Nortye Company Profile

(Get Free Report)

Adlai Nortye Ltd. (NASDAQ: ANL) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cancer and other serious diseases. The company’s research and development programs are centered on immuno-oncology and targeted therapies intended to address unmet medical needs.

Adlai Nortye’s pipeline has included buparlisib, an oral pan-PI3K inhibitor being studied in oncology, as well as AN0025, an investigational EP4 antagonist designed to affect pathways involved in tumor growth and immune response.